Renhai Cao1, Ebba Bråkenhielm1, Robert Pawliuk2, David Wariaro3, Mark J. Post4, Eric Wahlberg3, Philippe Leboulch2, 5, 6
& Yihai Cao11
Laboratory of Angiogenesis Research, Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden
2
Genetix Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
3
Department of Vascular Surgery, Karolinska Hospital, Stockholm, Sweden
4
Department of Medicine, Dartmouth Medical School, Lebanon, New Hampshire, USA
5
Harvard Medical School and Division of Genetics, Department of Medicine, Brigham & Women's Hospital, Boston, Massachusetts, USA
6
INSERM EMI 0111, Hopital Saint-Louis, Paris, France
Correspondence should be addressed to Yihai Cao yihai.cao@mtc.ki.se
and PDGFR-
by FGF-2 in newly formed blood vessels. Our data show that a specific combination of angiogenic factors establishes functional and stable vascular networks, and provides guidance for the ongoing clinical trials of angiogenic factors for the treatment of ischemic diseases.
